8-K: ReShape Lifesciences Announces Merger with Vyome Therapeutics and Asset Sale to Biorad Medisys Amidst Cost Reduction Efforts

ReShape Lifesciences has entered into a merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys, while also reporting a significant reduction in operating expenses.

Summary

• ReShape Lifesciences reported its financial results for the second quarter and six months ended June 30, 2024, alongside a strategic corporate update.
• The company has entered into a merger agreement with Vyome Therapeutics, where ReShape stockholders will own approximately 11.1% of the combined entity, subject to adjustments based on net cash at closing.
• Concurrently, ReShape has agreed to sell substantially all of its assets, excluding cash, to Biorad Medisys for $5.16 million in cash, also subject to adjustments.
• ReShape has significantly reduced its operating expenses by 45.4% in the first half of 2024 compared to the same period in 2023.
• Second quarter revenue was $2.0 million, a 12.8% decrease compared to the same period last year, primarily due to decreased sales volume attributed to GLP-1 pharmaceuticals.
• Gross profit for the second quarter was $1.1 million, slightly below the $1.2 million reported in the same period of 2023, but the gross profit margin increased to 57.7% from 53.0%.
• Sales and marketing expenses decreased by 69.2% to $0.7 million for the quarter, and general and administrative expenses decreased by 13.3% to $2.1 million.
• Research and development expenses decreased by 31.3% to $0.4 million for the quarter, as the company paused clinical work to preserve cash.
• As of June 30, 2024, the company had net working capital of approximately $2.9 million, including $1.2 million in cash and cash equivalents.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has made significant strides in cost reduction and strategic restructuring, the revenue decline and the need for a merger and asset sale suggest underlying challenges. The sentiment is cautiously optimistic due to the potential of the merger but tempered by the current financial performance.

Positives

• The merger with Vyome Therapeutics and asset sale to Biorad Medisys are expected to maximize value for shareholders.
• The company has achieved a significant reduction in operating expenses, demonstrating effective cost management.
• Gross profit margin has improved, indicating better efficiency in operations.
• The company has successfully negotiated a reduction in liquidation preference with Series C preferred stockholders, benefiting common stockholders.
• The company has moved to a targeted digital marketing campaign, resulting in a reduction of costs.

Negatives

• Revenue decreased by 12.8% in the second quarter and 13.9% for the first six months of 2024, primarily due to the impact of GLP-1 pharmaceuticals.
• Gross profit decreased slightly in the second quarter compared to the same period last year.
• The company has paused all clinical work to preserve cash, which may impact future product development.
• The company has experienced a reduction in sales personnel.

Risks

• The merger and asset sale are subject to various conditions, including stockholder approval, and may not be completed.
• The company's business may suffer due to uncertainty surrounding the merger and asset sale.
• The company faces risks related to economic, business, and competitive factors.
• The company's revenue is being negatively impacted by the adoption of GLP-1 pharmaceuticals.
• There is a risk that the merger and asset sale will not be consummated within the expected time period or at all.

Future Outlook

The company believes the merger with Vyome Therapeutics and the asset sale to Biorad Medisys present a significant opportunity for shareholders to capitalize on the potential of the newly formed entity.

Management Comments

• Paul F. Hickey, President and CEO, stated that the company continued to execute on its 2024 cost reduction plan, leading to approximately 45% lower operating expenses for the first half of the year.
• Paul F. Hickey also mentioned that the company coordinated both the merger agreement with Vyome Therapeutics and the concurrent asset purchase agreement with Biorad, successfully maximizing value for stockholders.
• Management believes that the presentation of non-GAAP financial information provides investors with greater transparency and facilitates comparison of operating results.

Industry Context

The decrease in sales volume due to the adoption of GLP-1 pharmaceuticals highlights a significant shift in the weight loss and metabolic health market, where pharmaceutical interventions are increasingly impacting the demand for medical devices and procedures. This is a trend that is affecting many companies in the medical device space.

Comparison to Industry Standards

• The 45.4% reduction in operating expenses is a significant achievement, especially when compared to other medical device companies that are struggling with profitability.
• The decrease in revenue due to GLP-1 adoption is a common challenge in the weight loss industry, with companies like Medtronic and Johnson & Johnson also facing similar headwinds in their bariatric surgery divisions.
• The merger and asset sale strategy is a unique approach to navigate the changing market, unlike companies that are focusing on product innovation or geographic expansion.

Stakeholder Impact

• Shareholders will be impacted by the merger with Vyome Therapeutics and the asset sale to Biorad Medisys, with existing ReShape stockholders owning approximately 11.1% of the combined company.
• Employees have been impacted by the reduction in staffing levels and changes in sales personnel.
• Customers may experience changes in product availability and support due to the asset sale.
• Suppliers may be affected by the change in ownership of the company's assets.

Next Steps

• The company will file a joint proxy statement/prospectus with the SEC in connection with the proposed merger and asset sale.
• A conference call will be held on August 15, 2024, to discuss the financial and operational results.
• The company will seek stockholder approval for the proposed merger and asset sale.

Key Dates

Keywords

Merger, Asset Sale, Vyome Therapeutics, Biorad Medisys, Cost Reduction, Operating Expenses, Financial Results, GLP-1, Weight Loss, Metabolic Health